<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39350092</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-230X</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>BMC gastroenterology</Title><ISOAbbreviation>BMC Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Long-term antibody response after the third dose of inactivated SARS-CoV-2 vaccine in MASLD patients.</ArticleTitle><Pagination><StartPage>329</StartPage><MedlinePgn>329</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">329</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12876-024-03402-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Metabolic dysfunction-associated steatotic liver disease (MASLD) patients are at an elevated risk of developing severe coronavirus disease 2019 (COVID-19). The objective of this study was to assess antibody responses and safety profiles six months after the third dose of the inactivated acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in MASLD patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study included MASLD patients and healthy volunteers without a history of SARS-CoV-2 infection. Blood samples were collected six months after receiving the third dose of the inactivated vaccine to measure the levels of neutralizing antibodies (NAbs) and anti-spike IgG antibodies against SARS-CoV-2.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 335 participants (214 MASLD patients and 121 healthy volunteers) were enrolled. The seroprevalence of NAb was 61.7% (132 of 214) in MASLD patients and 74.4% (90 of 121) in healthy volunteers, which was a significant difference (p = 0.018). Statistically significant differences in IgG seroprevalence were also observed between MASLD patients and healthy volunteers (p = 0.004). Multivariate analysis demonstrated that the severity of MASLD (OR, 2.97; 95% CI, 1.32-6.68; p = 0.009) and age (OR, 1.03; 95% CI, 1.01-1.06; p = 0.004) were independent risk factors for NAb negativity in MASLD patients. Moderate/severe MASLD patients had a lower NAb seroprevalence than mild MASLD patients (45.0% vs. 65.5%, p = 0.016).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Lower antibody responses were observed in MASLD patients six months after their third dose of the inactivated vaccine than in healthy volunteers, providing further assistance in monitoring patients who are more vulnerable to hypo-responsiveness to SARS-CoV-2 vaccines.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Cui</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Lianbang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghavamian</LastName><ForeName>Armin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xuemei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Gongzheng</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ru</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Ultrasound, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, 758 Hefei Road, Qingdao, Shandong, 266035, China. 543669972@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xinya</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Endocrine Glucose &amp; Lipids Metabolism and Brain Aging, Ministry of Education, Jinan, Shandong, 250021, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZR2022MH237</GrantID><Agency>Natural Science Foundation of Shandong Province</Agency><Country /></Grant><Grant><GrantID>ZR2023MH257</GrantID><Agency>Natural Science Foundation of Shandong Province</Agency><Country /></Grant><Grant><GrantID>82371916</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>No. tsqn202312352</GrantID><Agency>Taishan Scholar Foundation of Shandong Province</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Gastroenterol</MedlineTA><NlmUniqueID>100968547</NlmUniqueID><ISSNLinking>1471-230X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000706269">SARS-CoV-2 inactivated vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="Y">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibody response</Keyword><Keyword MajorTopicYN="N">Metabolic dysfunction-associated steatotic liver disease</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>23</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39350092</ArticleId><ArticleId IdType="pmc">PMC11441169</ArticleId><ArticleId IdType="doi">10.1186/s12876-024-03402-9</ArticleId><ArticleId IdType="pii">10.1186/s12876-024-03402-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization, Coronavirus (COVID-19). wwwwhoint. (2023). Accessed 8 Aug 2024.</Citation></Reference><Reference><Citation>Lapuente D, Winkler TH, Tenbusch M. B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. Cell Mol Immunol. 2024;21(2):144–58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805925</ArticleId><ArticleId IdType="pubmed">37945737</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-S64.</Citation><ArticleIdList><ArticleId IdType="pubmed">25920090</ArticleId></ArticleIdList></Reference><Reference><Citation>Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50.</Citation><ArticleIdList><ArticleId IdType="pubmed">20879883</ArticleId></ArticleIdList></Reference><Reference><Citation>Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–61.</Citation><ArticleIdList><ArticleId IdType="pubmed">35798021</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng MLP, Ng CH, Huang DQ, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S32–42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10029957</ArticleId><ArticleId IdType="pubmed">36517002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. J Hepatol. 2020;73(2):451–3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7141624</ArticleId><ArticleId IdType="pubmed">32278005</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou YJ, Zheng KI, Wang XB, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis. J Hepatol. 2020;73(3):719–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195041</ArticleId><ArticleId IdType="pubmed">32348790</ArticleId></ArticleIdList></Reference><Reference><Citation>Toutoudaki K, Androutsakos T. COVID-19 in individuals with Chronic Liver diseases. J Gastrointestin Liver Dis. 2024;33(1):7–10.</Citation><ArticleIdList><ArticleId IdType="pubmed">38554411</ArticleId></ArticleIdList></Reference><Reference><Citation>Srikanth S, Garg V, Subramanian L, et al. In-hospital outcomes in COVID-19 patients with non-alcoholic fatty liver disease by severity of obesity: insights from national inpatient sample 2020. World J Hepatol. 2024;16(6):912–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11212648</ArticleId><ArticleId IdType="pubmed">38948433</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan LN, Zhao ZX, Wang ZD, et al. Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 vaccine in China. Expert Rev Vaccines. 2022;21(10):1465–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">35861138</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleeson LE, Roche HM, Sheedy FJ. Obesity, COVID-19 and innate immunometabolism. Br J Nutr. 2021;125(6):628–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7520638</ArticleId><ArticleId IdType="pubmed">32892755</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Gorman P, Norris S. Exercising in the COVID-19 era: implications in non-alcoholic fatty liver disease (NAFLD). BMJ open Gastroenterol. 2021;8(1):e000568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8228576</ArticleId><ArticleId IdType="pubmed">34168043</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew KL, Tan SS, Saw S, et al. Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection. Clin Microbiol Infect. 2020;26(9):1256.e9-1256.e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7282795</ArticleId><ArticleId IdType="pubmed">32531475</ArticleId></ArticleIdList></Reference><Reference><Citation>Psaridi L, Maltezou HC, Simonidou S, et al. Neutralizing antibody responses in healthcare personnel after three doses of mRNA BNT162b2 vaccine and association with baseline characteristics and past SARS-CoV-2 infection. Vaccine. 2022;40(40):5752–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388445</ArticleId><ArticleId IdType="pubmed">36008235</ArticleId></ArticleIdList></Reference><Reference><Citation>Simão AL, Palma CS, Izquierdo-Sanchez L, et al. Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease. JHEP Rep 2023, 5(5):100697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9939238</ArticleId><ArticleId IdType="pubmed">36844943</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet (London England). 2021;398(10316):2093–100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8555967</ArticleId><ArticleId IdType="pubmed">34756184</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz S. BNT162b2 vaccine booster and Covid-19 mortality. N Engl J Med. 2022;386(10):1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">35139267</ArticleId></ArticleIdList></Reference><Reference><Citation>Miele M, Busà R, Russelli G, et al. Analysis of the specific Immune response after the third dose of mRNA COVID-19 vaccines in Organ Transplant recipients: possible Spike-S1 reactive IgA signature in Protection from SARS-CoV-2 infection. Microorganisms. 2022;10:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9415050</ArticleId><ArticleId IdType="pubmed">36013981</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun. 2021;12(1):6379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8569006</ArticleId><ArticleId IdType="pubmed">34737312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mochizuki T, Hori T, Yano K, et al. Factors Associated with Change in SARS-CoV-2 antibody titers from three to six months after the administration of the BNT162b2 mRNA COVID-19 vaccine among Healthcare Workers in Japan: a prospective study. Internal medicine (Tokyo, Japan). 2022;61(8):1139–43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9107982</ArticleId><ArticleId IdType="pubmed">35185050</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y, Mandel M, Bar-On YM et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385(24);e85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609604</ArticleId><ArticleId IdType="pubmed">34706170</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin EG, Lustig Y, Cohen C et al. Waning Immune Humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi RS, Singal AG, Cuthbert JA, et al. Lactulose vs polyethylene glycol 3350–electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014;174(11):1727–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5609454</ArticleId><ArticleId IdType="pubmed">25243839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamaguchi M, Kojima T, Itoh Y, et al. The severity of Ultrasonographic findings in nonalcoholic fatty liver Disease reflects the metabolic syndrome and visceral Fat Accumulation. Am J Gastroenterol. 2007;102(12):2708–15.</Citation><ArticleIdList><ArticleId IdType="pubmed">17894848</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraioli G, Monteiro LBS. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019;25(40):6053–62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6824276</ArticleId><ArticleId IdType="pubmed">31686762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquissi FC. Immune imbalances in non-alcoholic fatty liver disease: from general biomarkers and neutrophils to Interleukin-17 Axis activation and new therapeutic targets. Front Immunol. 2016;7:490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5104753</ArticleId><ArticleId IdType="pubmed">27891128</ArticleId></ArticleIdList></Reference><Reference><Citation>Proctor MJ, McMillan DC, Morrison DS, et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 2012;107(4):695–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3419948</ArticleId><ArticleId IdType="pubmed">22828611</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Azab B, Camacho-Rivera M, et al. Average values and Racial Differences of Neutrophil Lymphocyte Ratio among a nationally Representative Sample of United States subjects. PLoS ONE. 2014;9(11).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4223021</ArticleId><ArticleId IdType="pubmed">25375150</ArticleId></ArticleIdList></Reference><Reference><Citation>Alukal JJ, Naqvi HA, Thuluvath PJ. Vaccination in Chronic Liver Disease: an update. J Clin Exp Hepatol. 2022;12(3):937–47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8710401</ArticleId><ArticleId IdType="pubmed">34975241</ArticleId></ArticleIdList></Reference><Reference><Citation>McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis. 2000;181(2):757–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">10669371</ArticleId></ArticleIdList></Reference><Reference><Citation>Roni DA, Pathapati RM, Kumar AS, et al. Safety and efficacy of hepatitis B vaccination in cirrhosis of liver. Adv Virol. 2013;2013:196704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690205</ArticleId><ArticleId IdType="pubmed">23840211</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Hou Z, Liu J, et al. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study. J Hepatol. 2021;75(2):439–41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185617</ArticleId><ArticleId IdType="pubmed">33905793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai J, Wang J, Liu D, et al. Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2022;20(7):1516-24 e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8686447</ArticleId><ArticleId IdType="pubmed">34942370</ArticleId></ArticleIdList></Reference><Reference><Citation>Toutoudaki K, Dimakakou M, Androutsakos T. Efficacy, Safety and immunogenicity of Anti-SARS-CoV-2 vaccines in patients with cirrhosis: a narrative review. Vaccines (Basel). 2023;11(2).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9966438</ArticleId><ArticleId IdType="pubmed">36851329</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhang Q, Ai J, et al. Correction to: Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study. Hepatol Int. 2024;18(3):1062–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">37823938</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, Li X, Zhang L, et al. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7(1):141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047469</ArticleId><ArticleId IdType="pubmed">35484110</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CB, Farzan M, Chen B, et al. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y-S, Hsieh S-M, Tsai F-C, et al. Serological responses to COVID-19 vaccination in patients with chronic liver diseases. J Formos Med Assoc. 2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">38906731</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Li X, Zhao X, et al. Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: a multicenter study. Clin Res Hepatol Gastroenterol. 2023;47(7).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10234691</ArticleId><ArticleId IdType="pubmed">37269896</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Xing S, Liang D et al. Differential antibody response to inactivated COVID-19 vaccines in healthy subjects. Frontiers in cellular and infection microbiology. 2021;11:791660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8716725</ArticleId><ArticleId IdType="pubmed">34976867</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Li S, Xu P, et al. Analysis of neutralizing antibodies to COVID-19 inactivated or subunit recombinant vaccines in hospitalized patients with liver dysfunction. Front Immunol. 2023;14:1084646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9889857</ArticleId><ArticleId IdType="pubmed">36742314</ArticleId></ArticleIdList></Reference><Reference><Citation>Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020;69(8):1545–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32414813</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KS, Lam LK, Hui RWH, et al. Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients. Clin Mol Hepatol. 2022;28(3):553–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9293606</ArticleId><ArticleId IdType="pubmed">35545127</ArticleId></ArticleIdList></Reference><Reference><Citation>Müller L, Andrée M, Moskorz W, et al. Age-dependent Immune response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2021;73(11):2065–72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135422</ArticleId><ArticleId IdType="pubmed">33906236</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier DA, Ferreira I, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596(7872):417–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373615</ArticleId><ArticleId IdType="pubmed">34192737</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>